Effectiveness of metyrapone in treating cushing's syndrome: A retrospective multicenter study in 195 patients

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 11, 2015, Pages 4146-4154

  Daniel, Eleni ^a   Aylwin, Simon ^b   Mustafa, Omar ^b   Ball, Steve ^c,d   Munir, Atif ^d   Boelaert, Kristien ^e   Chortis, Vasileios ^e   Cuthbertson, Daniel J ^f   Daousi, Christina ^f   Rajeev, Surya P ^f   Davis, Julian ^g   Cheer, Kelly ^h   Drake, William ⁱ   Gunganah, Kirun ⁱ   Grossman, Ashley ^j   Gurnell, Mark ^k   Powlson, Andrew S ^k   Karavitaki, Niki ^e,j   Huguet, Isabel ^j   Kearney, Tara ^l   Mohit, Kumar ^l   Meeran, Karim ^m   Hill, Neil ^m   Rees, Aled ⁿ   Lansdown, Andrew J ⁿ   Trainer, Peter J ^o   Minder, Anna Elisabeth H ^o   Newell Price, John ^a   more..

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h MANCHESTER ROYAL INFIRMARY   (United Kingdom)

ⁱ ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^j CHURCHILL HOSPITAL   (United Kingdom)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^l SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^m IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁿ CARDIFF UNIVERSITY   (United Kingdom)

^o CHRISTIE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOTROPIN; GLUCOCORTICOID; KETOCONAZOLE; METYRAPONE; MITOTANE; ENZYME INHIBITOR; HYDROCORTISONE;

ACNE; ADOLESCENT; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL HYPERPLASIA; ADRENAL INSUFFICIENCY; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BIOCHEMISTRY; CASE STUDY; CHEMICAL PARAMETERS; CHILD; CONTROLLED STUDY; CUSHING SYNDROME; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; ECTOPIC CORTICOTROPIN PRODUCTION; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERANDROGENISM; HYPERCORTISOLISM; HYPOADRENALISM; HYPOGLYCEMIA; HYPOTENSION; INFANT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PRESCHOOL CHILD; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT DURATION; UNIVERSITY HOSPITAL; VERY ELDERLY; ACTH-SECRETING PITUITARY ADENOMA; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; MIDDLE AGED; MULTICENTER STUDY; PITUITARY NEOPLASMS; TREATMENT OUTCOME; URINE; YOUNG ADULT;

ACTH-SECRETING PITUITARY ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CUSHING SYNDROME; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; HYDROCORTISONE; INFANT; MALE; METYRAPONE; MIDDLE AGED; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84956725273     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2616     Document Type: Article

References (28)

1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006;367:1605-1617.
2. Basina M, Liu H, Hoffman AR, Feldman D. Successful long-term treatment of Cushing disease with mifepristone (RU486). Endocr Pract. 2012;18:e114-e120.
3. Nieman LK. Medical therapy of Cushing's disease. Pituitary. 2002; 5:77-82.
4. Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing's disease: is it worth a try? J Clin Endocrinol Metab. 2014;99:1623-1630.
5. United States Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 2013. http://www.fda.gov/Drugs/DrugSafety/ucm362415.htm
6. Trainer PJ. Next generation medical therapy for Cushing's syndrome-can we measure a benefit? J Clin Endocrinol Metab. 2014; 99:1157-1160.
7. European Medicines Agency. Recommendation for maintenance of orphan designation at the time of marketing authorisation: ketoconazole HRA (ketoconazole) for the treatment of Cushing's syndrome. 2015. http://www.ema.europa.eu/docs/en-GB/document-library/Orphan-review/2015/01/WC500181644.pdf
8. Liddle GW, Island D, Lance EM, Harris AP. Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11-hydroxylation. J Clin Endocrinol Metab. 1958; 18:906-912.
9. Sonino N, Chow D, Levine LS, New MI. Clinical response to metyrapone as indicated by measurement of mineralocorticoids and glucocorticoids in normal children. Clin Endocrinol (Oxf). 1981; 14:31-39.
10. Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf). 1991;35:169-178.
11. Trainer PJ, Eastment C, Grossman AB, Wheeler MJ, Perry L, Besser GM. The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing's syndrome. Clin Endocrinol (Oxf). 1993;39:441-443.
12. Nieman LK. Medical therapy of hypercortisolism (Cushing's syndrome). UpToDate. Updated September 24, 2014. Accessed May 19, 2015.
13. Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM. Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol. Q J Med. 1979;48:465-472.
14. Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, Edwards CR, Besser GM.Metyrapone in long-term management of Cushing's disease. Br Med J. 1977;2:215-217.
15. RossWM,Evered DC, Hunter P, Benaim M, Cook D, Hall R. Treatment of Cushing's disease with adrenal blocking drugs and megavoltage therapy to the pituitary. Clin Radiol. 1979;30:149-153.
16. Child DF, Burke CW, Burley DM, Rees LH, Fraser TR. Drug controlled of Cushing's syndrome. Combined aminoglutethimide and metyrapone therapy. Acta Endocrinol (Copenh). 1976;82:330-341.
17. Doi M, Sugiyama T, Izumiyama H, Yoshimoto T, Hirata Y. Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. Endocr J. 2010;57:1061-1069.
18. Daniel E, Newell-Price JD. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome. Eur J Endocrinol. 2015;172:R263-R280.
19. Valassi E, Crespo I, Gich I, Rodriguez J, Webb SM. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome. Clin Endocrinol (Oxf). 2012;77:735-742.
20. Corcuff JB, Young J, Masquefa-Giraud P, Chanson P, Baudin E, Tabarin A. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol. 2015;172:473-481.
21. Kamenick P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab. 2011;96:2796-2804.
22. Touitou Y, Moolenaar AJ, Bogdan A, Auzéby A, Luton JP. o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis. Eur J Clin Pharmacol. 1985;29:483-487.
23. Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med. 2010;362:1846-1848.
24. Coppage WS Jr, Island D, Smith M, Liddle GW. Inhibition of aldosterone secretion and modification of electrolyte excretion in man by a chemical inhibitor of 11-hydroxylation. J Clin Invest. 1959; 38:2101-2110.
25. Monaghan PJ, Owen LJ, Trainer PJ, Brabant G, Keevil BG, Darby D. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11-hydroxylase inhibitor metyrapone. Ann Clin Biochem. 2011;48:441-446.
26. Owen LJ, Halsall DJ, Keevil BG. Cortisol measurement in patients receiving metyrapone therapy. Ann Clin Biochem. 2010;47:573-575.
27. Monaghan PJ, Keevil BG, Trainer PJ. The use of mass spectrometry to improve the diagnosis and the management of the HPA axis. Rev Endocr Metab Disord. 2013;14:143-157.
28. Feelders RA, Hofland LJ. Medical treatment of Cushing's disease. J Clin Endocrinol Metab. 2013;98:425-438.